SG11201903483VA - Compositions and methods for treating ezh2-mediated cancer - Google Patents
Compositions and methods for treating ezh2-mediated cancerInfo
- Publication number
- SG11201903483VA SG11201903483VA SG11201903483VA SG11201903483VA SG11201903483VA SG 11201903483V A SG11201903483V A SG 11201903483VA SG 11201903483V A SG11201903483V A SG 11201903483VA SG 11201903483V A SG11201903483V A SG 11201903483VA SG 11201903483V A SG11201903483V A SG 11201903483VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- gustave
- medicine
- new york
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662414195P | 2016-10-28 | 2016-10-28 | |
| PCT/US2017/058718 WO2018081530A1 (fr) | 2016-10-28 | 2017-10-27 | Compositions et procédés pour le traitement du cancer à médiation par l'ezh2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201903483VA true SG11201903483VA (en) | 2019-05-30 |
Family
ID=62024052
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201903483VA SG11201903483VA (en) | 2016-10-28 | 2017-10-27 | Compositions and methods for treating ezh2-mediated cancer |
| SG10202104386UA SG10202104386UA (en) | 2016-10-28 | 2017-10-27 | Compositions and methods for treating ezh2-mediated cancer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202104386UA SG10202104386UA (en) | 2016-10-28 | 2017-10-27 | Compositions and methods for treating ezh2-mediated cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20190255041A1 (fr) |
| EP (1) | EP3532464A4 (fr) |
| JP (1) | JP2019537585A (fr) |
| KR (1) | KR20190084063A (fr) |
| CN (1) | CN110167924A (fr) |
| AU (2) | AU2017348322B8 (fr) |
| CA (1) | CA3041840A1 (fr) |
| EA (1) | EA201991071A1 (fr) |
| IL (1) | IL266053A (fr) |
| MX (1) | MX2019004950A (fr) |
| SG (2) | SG11201903483VA (fr) |
| WO (1) | WO2018081530A1 (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180046208A (ko) * | 2016-10-27 | 2018-05-08 | 삼성전자주식회사 | 음성 명령에 기초하여 애플리케이션을 실행하는 방법 및 장치 |
| US20190255041A1 (en) | 2016-10-28 | 2019-08-22 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating ezh2-mediated cancer |
| AU2017370694A1 (en) | 2016-12-08 | 2019-07-25 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating CDK4/6-mediated cancer |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| CA3092677A1 (fr) | 2018-03-06 | 2019-09-12 | Icahn School Of Medicine At Mount Sinai | Composes de degradation/interruption de serine threonine kinase (akt) et procedes d'utilisation |
| LT3784663T (lt) | 2018-04-23 | 2023-10-25 | Celgene Corporation | Pakeistieji 4-aminoizoindolin-1,3-diono junginiai ir jų naudojimas limfomos gydymui |
| CN112457365B (zh) * | 2019-09-09 | 2023-06-09 | 中国医学科学院药物研究所 | 一类靶向蛋白质水解通路的功能分子及其制备和应用 |
| CN110862434B (zh) * | 2019-10-28 | 2021-07-06 | 中山大学 | 一种可促进TGF-β1蛋白靶向降解的化合物及其制备方法与应用 |
| KR102505664B1 (ko) * | 2019-10-31 | 2023-03-03 | 재단법인 대구경북첨단의료산업진흥재단 | Ezh2 저해제 및 e3 리가제 바인더를 포함하는 화합물 및 이를 유효성분으로 함유하는 ezh2 관련 질환의 예방 또는 치료용 약학적 조성물 |
| CN111303133A (zh) * | 2020-03-25 | 2020-06-19 | 清华大学 | 降解ezh2蛋白的小分子化合物 |
| CN112920176B (zh) * | 2020-05-25 | 2022-11-04 | 四川大学华西医院 | 可诱导prc2蛋白复合物核心亚基降解的双功能化合物和药物组合物及应用 |
| JP7387907B2 (ja) * | 2020-08-13 | 2023-11-28 | ハンミ ファーマシューティカル カンパニー リミテッド | 新規なジオキソロイソキノリノン誘導体化合物及びその用途｛ｎｏｖｅｌ ｄｉｏｘｏｌｏｉｓｏｑｕｉｎｏｌｉｎｏｎｅ ｄｅｒｉｖａｔｉｖｅｓ ａｎｄ ｕｓｅ ｔｈｅｒｅｏｆ｝ |
| CN113214203A (zh) * | 2020-12-16 | 2021-08-06 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 基于ezh2蛋白降解的小分子化合物及其应用 |
| WO2022159650A1 (fr) * | 2021-01-22 | 2022-07-28 | Icahn School Of Medicine At Mount Sinai | Composés hétérobifonctionnels utilisés en tant qu'agents de dégradation de l'eef1a2 |
| US20230346953A1 (en) * | 2021-04-30 | 2023-11-02 | Northwestern University | Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhancer zeste homolog 2 (ezh2) and proteolysis-targeting chimeric derivatives thereof (protacs) that induce degradation of ezh2 |
| WO2023205701A1 (fr) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Hétérocycles macrocycliques et leurs utilisations |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5691147A (en) | 1994-06-02 | 1997-11-25 | Mitotix, Inc. | CDK4 binding assay |
| US6486214B1 (en) | 1997-09-10 | 2002-11-26 | Rutgers, The State University Of New Jersey | Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby |
| WO2001060814A2 (fr) | 2000-02-15 | 2001-08-23 | Sugen, Inc. | Inhibiteurs de la proteine kinase 2-indolinone a substitution pyrrole |
| JP5567339B2 (ja) | 2006-09-15 | 2014-08-06 | セルジーン コーポレイション | Ｎ−メチルアミノメチルイソインドール化合物、それを含む組成物、及びその使用方法 |
| WO2008109104A1 (fr) | 2007-03-07 | 2008-09-12 | The Regents Of The University Of California | Inhibiteurs bivalents de protéine kinase akt |
| US8377937B2 (en) | 2007-07-05 | 2013-02-19 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| US20110172107A1 (en) | 2008-04-30 | 2011-07-14 | Fox Chase Cancer Center | Assay for identifying agents that modulate epigenetic silencing, and agents identified thereby |
| CN102984941B (zh) | 2009-09-04 | 2016-08-17 | 密执安大学评议会 | 用于治疗白血病的组合物和方法 |
| RS58523B1 (sr) | 2010-02-11 | 2019-04-30 | Celgene Corp | Derivati arilmetoksi izoindolina i kombinacije koje ih obuhvataju i postupci njihove upotrebe |
| WO2012078492A1 (fr) | 2010-12-06 | 2012-06-14 | Celgene Corporation | Traitement d'association avec du lénalidomide et un inhibiteur de cdk pour traiter le myélome multiple |
| KR102204989B1 (ko) | 2012-01-12 | 2021-01-20 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| WO2013170147A1 (fr) | 2012-05-11 | 2013-11-14 | Yale University | Composés utiles pour stimuler la dégradation des protéines et procédés utilisant ceux-ci |
| WO2014063061A1 (fr) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Petites molécules marquées de façon hydrophobe en tant qu'inducteurs de la dégradation de protéine |
| HUE040323T2 (hu) | 2012-12-21 | 2019-02-28 | Epizyme Inc | PRMT5-inhibitorok és alkalmazásaik |
| RU2670762C2 (ru) | 2013-12-31 | 2018-10-25 | Хуаньчжу Фарма Ко., Лтд. | Производные 6-(пиримидиноаминопиридин)бензоимидазола, полезные для лечения рака |
| WO2015104677A1 (fr) * | 2014-01-10 | 2015-07-16 | Piramal Enterprises Limited | Composés hétérocycliques en tant qu'inhibiteurs de ezh2 |
| MX2016013563A (es) * | 2014-04-14 | 2017-05-09 | Arvinas Inc | Moduladores de la proteolisis basados en imida y metodos de uso asociados. |
| CA2952051C (fr) | 2014-06-13 | 2023-09-12 | Trustees Of Tufts College | Agents therapeutiques actives par fap, et utilisations associees |
| CA2964629A1 (fr) * | 2014-11-06 | 2016-05-12 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs d'ezh2 et leurs utilisations |
| US10479997B2 (en) | 2014-12-01 | 2019-11-19 | Novartis Ag | Compositions and methods for diagnosis and treatment of prostate cancer |
| CN107257800B (zh) * | 2014-12-23 | 2020-06-30 | 达纳-法伯癌症研究所股份有限公司 | 通过双功能分子诱导靶蛋白降解的方法 |
| WO2016106518A1 (fr) * | 2014-12-29 | 2016-07-07 | 深圳市日上光电股份有限公司 | Boîtier de lampe d'éclairage intégré de ligne conductrice |
| TWI698436B (zh) | 2014-12-30 | 2020-07-11 | 美商佛瑪治療公司 | 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶 |
| EP3244927A1 (fr) | 2015-01-16 | 2017-11-22 | Vedantra Pharmaceuticals Inc. | Compositions de vésicules lipidiques multilamellaires comprenant un variant de kinase du lymphome anaplasique (alk) conjugué et leurs utilisations |
| AU2016232705C1 (en) * | 2015-03-18 | 2021-06-17 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| US10988737B2 (en) | 2015-04-28 | 2021-04-27 | Universite De Strasbourg | Clinical gene signature-based human cell culture model and uses thereof |
| RU2719477C2 (ru) | 2015-06-22 | 2020-04-17 | Оно Фармасьютикал Ко., Лтд. | Соединение, ингибирующее brk |
| CN105085620B (zh) | 2015-06-25 | 2018-05-08 | 中山大学附属第一医院 | 一种靶向泛素化降解Smad3的化合物 |
| WO2017007612A1 (fr) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Procédés pour induire la dégradation ciblée de protéines par des molécules bifonctionnelles |
| WO2017011371A1 (fr) * | 2015-07-10 | 2017-01-19 | Arvinas, Inc | Modulateurs de protéolyse à base de mdm2 et méthodes d'utilisation associées |
| WO2017011590A1 (fr) * | 2015-07-13 | 2017-01-19 | Arvinas, Inc. | Modulateurs de protéolyse à base d'alanine et procédés d'utilisation associés |
| US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
| CA2996685A1 (fr) | 2015-09-03 | 2017-03-09 | Aileron Therapeutics, Inc. | Macrocycles peptidomimetiques et leurs utilisations |
| RU2018120330A (ru) * | 2015-11-02 | 2019-12-04 | Йейл Юниверсити | Химерные соединения, осуществляющие нацеливание для протеолиза, и способы их получения и применения |
| US11174250B2 (en) | 2016-03-01 | 2021-11-16 | Propellon Therapeutics Inc. | Substituted carboxamides as inhibitors of WDR5 protein-protein binding |
| EA038109B1 (ru) | 2016-03-01 | 2021-07-07 | Пропеллон Терапьютикс Инк. | Ингибиторы связывания белка wdr5 с белками |
| CN109071552B (zh) | 2016-04-22 | 2022-06-03 | 达纳－法伯癌症研究所公司 | 细胞周期蛋白依赖性激酶4/6(cdk4/6)通过cdk4/6抑制剂与e3连接酶配体的缀合的降解及使用方法 |
| WO2017197051A1 (fr) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Dégronimères de c3-glutarimide liés à une amine pour la dégradation de protéines cibles |
| WO2017197055A1 (fr) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Dégronimères hétérocycliques pour la dégradation de protéines cibles |
| US20180072741A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
| US10160763B2 (en) | 2016-09-13 | 2018-12-25 | Vanderbilt University | WDR5 inhibitors and modulators |
| US20190255041A1 (en) | 2016-10-28 | 2019-08-22 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating ezh2-mediated cancer |
| AU2017370694A1 (en) | 2016-12-08 | 2019-07-25 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating CDK4/6-mediated cancer |
| US11052091B2 (en) | 2016-12-21 | 2021-07-06 | Ono Pharmaceutical Co., Ltd. | BRK inhibitory compound |
| WO2019113071A1 (fr) | 2017-12-05 | 2019-06-13 | Icahn School Of Medicine At Mount Sinai | Compositions et méthodes de traitement de cancer à médiation par alk |
| WO2019165189A1 (fr) | 2018-02-22 | 2019-08-29 | Icahn School Of Medicine At Mount Sinai | Composés de dégradation/perturbation de la protéine arginine méthyltransférase 5 (prmt5) et méthodes d'utilisation |
| CA3092677A1 (fr) | 2018-03-06 | 2019-09-12 | Icahn School Of Medicine At Mount Sinai | Composes de degradation/interruption de serine threonine kinase (akt) et procedes d'utilisation |
| WO2019222380A1 (fr) | 2018-05-15 | 2019-11-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Formulations et méthodes de prévention et de traitement des métastases tumorales et de la tumorigenèse |
| EP3810145A4 (fr) | 2018-06-21 | 2022-06-01 | Icahn School of Medicine at Mount Sinai | Composés de dégradation/désintégration de la protéine 5 à domaine de répétition wd40 (wdr5) et méthodes d'utilisation |
| CN114269749A (zh) | 2019-06-10 | 2022-04-01 | 苏特罗生物制药公司 | 5H-吡咯并[3,2-d]嘧啶-2,4-二氨基化合物及其抗体偶联物 |
| WO2021021904A1 (fr) | 2019-07-30 | 2021-02-04 | The Scripps Research Institute | Inhibiteurs pharmacologiques du domaine enl yeats |
| US20210395244A1 (en) | 2020-06-01 | 2021-12-23 | Icahn School Of Medicine At Mount Sinai | Mitogen-activated protein kinase kinase (mek) degradation compounds and methods of use |
| CN112778303A (zh) | 2020-12-31 | 2021-05-11 | 武汉九州钰民医药科技有限公司 | Cdk4/6激酶抑制剂shr6390的制备方法 |
-
2017
- 2017-10-27 US US16/345,591 patent/US20190255041A1/en not_active Abandoned
- 2017-10-27 CA CA3041840A patent/CA3041840A1/fr not_active Abandoned
- 2017-10-27 EP EP17863645.2A patent/EP3532464A4/fr active Pending
- 2017-10-27 KR KR1020197015152A patent/KR20190084063A/ko not_active Application Discontinuation
- 2017-10-27 CN CN201780081246.8A patent/CN110167924A/zh active Pending
- 2017-10-27 AU AU2017348322A patent/AU2017348322B8/en active Active
- 2017-10-27 JP JP2019522841A patent/JP2019537585A/ja active Pending
- 2017-10-27 MX MX2019004950A patent/MX2019004950A/es unknown
- 2017-10-27 SG SG11201903483VA patent/SG11201903483VA/en unknown
- 2017-10-27 WO PCT/US2017/058718 patent/WO2018081530A1/fr unknown
- 2017-10-27 SG SG10202104386UA patent/SG10202104386UA/en unknown
- 2017-10-27 EA EA201991071A patent/EA201991071A1/ru unknown
-
2019
- 2019-04-15 IL IL266053A patent/IL266053A/en unknown
-
2020
- 2020-07-10 US US16/926,418 patent/US11510920B2/en active Active
-
2022
- 2022-03-03 AU AU2022201488A patent/AU2022201488A1/en active Pending
- 2022-11-01 US US17/978,696 patent/US20230114294A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017348322B8 (en) | 2021-12-23 |
| KR20190084063A (ko) | 2019-07-15 |
| EP3532464A1 (fr) | 2019-09-04 |
| US11510920B2 (en) | 2022-11-29 |
| JP2019537585A (ja) | 2019-12-26 |
| CA3041840A1 (fr) | 2018-05-03 |
| SG10202104386UA (en) | 2021-05-28 |
| AU2017348322A8 (en) | 2021-12-23 |
| AU2022201488A1 (en) | 2022-03-24 |
| AU2017348322A1 (en) | 2019-06-13 |
| US20230114294A1 (en) | 2023-04-13 |
| US20190255041A1 (en) | 2019-08-22 |
| EA201991071A1 (ru) | 2019-11-29 |
| AU2017348322B2 (en) | 2021-12-09 |
| CN110167924A (zh) | 2019-08-23 |
| IL266053A (en) | 2019-06-30 |
| US20200338070A1 (en) | 2020-10-29 |
| EP3532464A4 (fr) | 2020-07-08 |
| WO2018081530A1 (fr) | 2018-05-03 |
| MX2019004950A (es) | 2019-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201903483VA (en) | Compositions and methods for treating ezh2-mediated cancer | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201811225RA (en) | Ar+ breast cancer treatment methods | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201808306PA (en) | Treatment of cancer with tg02 | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201811416VA (en) | Crystalline solid forms of a bet inhibitor | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201903770UA (en) | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders | |
| SG11201810333UA (en) | Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to treat b-cell proliferative disorders | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
| SG11201810078PA (en) | Stabilized pre-fusion rsv f proteins | |
| SG11201809237RA (en) | Oxaborole esters and uses thereof | |
| SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors | |
| SG11201900043TA (en) | Antibody formulations |